Browsing by title
Now showing items 1990-2009 of 4698
-
Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.
(NATURE PUBLISHING GROUP, 2017-08-22)BACKGROUND: Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer. METHODS: We analysed ... -
Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.
(2017-02)Background Myelosuppression is common in patients with progressive castration-resistant prostate cancer and bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; understanding ... -
Hematopoietic Stem Cell (HSC)-Independent Progenitors Are Susceptible to Mll-Af9-Induced Leukemic Transformation.
(MDPI, 2023-07-14)Infant acute myeloid leukemia (AML) is a heterogeneous disease, genetically distinct from its adult counterpart. Chromosomal translocations involving the KMT2A gene (MLL) are especially common in affected infants of less ... -
Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model.
(BMJ PUBLISHING GROUP, 2021-01-01)Patients with glioblastoma (GBM) have a poor prognosis, and inefficient delivery of drugs to tumors represents a major therapeutic hurdle. Hematopoietic stem cell (HSC)-derived myeloid cells efficiently home to GBM and ... -
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA.
(2021-11-17)Gemcitabine or 5-fluorouracil (5-FU) based treatments can be selected for pancreatic cancer. Equilibrative nucleoside transporter 1 (hENT1) predicts adjuvant gemcitabine treatment benefit over 5-FU. Cytidine deaminase ... -
HER-3 Expression and MEK Activation in Non-small Cell Lung Cancer
(Research Square, 2020-08-26)<h4>Background: </h4> HER-3 has a role in pathogenesis and development of resistance to targeted therapies in non-small cell lung cancer (NSCLC). MethodsWe analysed tumour samples from 45 patients with adenocarcinoma of ... -
HER2 Inhibition in Gastric Cancer-Novel Therapeutic Approaches for an Established Target.
(MDPI, 2022-08-06)Gastric cancer is a leading cause of cancer-related deaths globally. Human epidermal growth receptor 2 (HER2) overexpression of HER2 gene amplification is present in 20% of gastric cancers and defines a subset amenable to ... -
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.
(ELSEVIER, 2022-08-16)BACKGROUND: Oestrogen receptor positive/ human epidermal growth factor receptor positive (ER+/HER2+) breast cancers (BCs) are less responsive to endocrine therapy than ER+/HER2- tumours. Mechanisms underpinning the ... -
HER3 expression and MEK activation in non-small-cell lung carcinoma.
(TAYLOR & FRANCIS LTD, 2021-04-09)AIM: We explore HER3 expression in lung adenocarcinoma (adeno-NSCLC) and identify potential mechanisms of HER3 expression. MATERIALS & METHODS: Tumor samples from 45 patients with adeno-NSCLC were analyzed. HER3 and HER2 ... -
HER3 Is an Actionable Target in Advanced Prostate Cancer.
(AMER ASSOC CANCER RESEARCH, 2021-12-15)It has been recognized for decades that ERBB signaling is important in prostate cancer, but targeting ERBB receptors as a therapeutic strategy for prostate cancer has been ineffective clinically. However, we show here that ... -
HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.
(AMER ASSOC CANCER RESEARCH, 2018-04-15)Purpose: Recent studies have highlighted a role of HER3 in HER2-driven cancers (e.g., breast cancer), implicating the upregulation of the receptor in resistance to HER-targeted therapies and Hsp90 inhibitors (e.g., AUY922). ... -
Herding clonal evolution to overcome drug resistance in high-grade serous ovarian cancer
(Institute of Cancer Research (University Of London), 2024-06-04)Ovarian cancer (OC) is one of the most common malignancies responsible for cancer-related deaths in women, and finding new treatment strategies is an area of unmet clinical need. To investigate how the concepts of cancer ... -
HERMES: Delivery of a Speedy Prostate Cancer Treatment.
(ELSEVIER SCIENCE LONDON, 2022-01-26) -
HETEROARYL INHIBITORS OF PAD4
(2018-03-15) -
Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses.
(NATURE PUBLISHING GROUP, 2019-08-02)Breast cancer is a highly heterogeneous disease. Although differences between intrinsic breast cancer subtypes have been well studied, heterogeneity within each subtype, especially luminal-A cancers, requires further ... -
Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.
(BIOMED CENTRAL LTD, 2016-04-01)BACKGROUND: Gene expression is widely used for the characterisation of breast cancers. Variability due to tissue heterogeneity or measurement error or systematic change due to peri-surgical procedures can affect measurements ... -
Heterogeneous proliferative potential in regenerative adult newt cardiomyocytes.
(COMPANY BIOLOGISTS LTD, 2003-10-01)Adult newt cardiomyocytes, in contrast to their mammalian counterparts, can proliferate after injury and contribute to the functional regeneration of the heart. In order to understand the mechanisms underlying this plasticity ... -
Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.
(BIOMED CENTRAL LTD, 2016-11-14)BACKGROUND: Molecular intratumour heterogeneity (ITH) is common in clear cell renal carcinomas (ccRCCs). However, it remains unknown whether this is mirrored by heterogeneity of drug responses between metastases in the ...